Pancreatic Cancer

Evidence-based overview of Boswellia in pancreatic cancer, including orthotopic tumour suppression and COX-2-related mechanisms

Pancreatic cancer is one of the more compelling Boswellia settings from a preclinical standpoint because orthotopic model data exists.

Overview

The strongest pancreatic data centres on growth suppression, metastasis reduction, and COX-2, NF-κB, MMP-9, and VEGF modulation in vivo.

Key preclinical data

Orthotopic nude-mouse work showed suppression of pancreatic tumour growth and metastasis
AKBA downregulated COX-2, VEGF, MMP-9, and NF-κB-related signalling in tumour tissue
These findings give Boswellia more credibility here than a purely cell-line-only evidence base would

Clinical positioning

This remains a preclinical area, but an unusually meaningful one because pancreatic cancer is so hard to treat and orthotopic evidence is more translationally useful than simple cell-line work alone.

References

Boswellic acid suppresses growth and metastasis of human pancreatic tumours in an orthotopic nude mouse model
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0026943

Jump to another Boswellia page

Core pages

Mechanism deep dives

Practical pages

Cancer-type pages

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.